Hope Bancorp Inc.

4 days ago · seekingalpha.com

Hope Bancorp, Inc. (HOPE) Q3 2026 Earnings Call Transcript

4 days ago · zacks.com

Although the revenue and EPS for Hope Bancorp (HOPE) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

4 days ago · zacks.com

Hope Bancorp (HOPE) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.25 per share a year ago.

27 days ago · zacks.com

Hope Bancorp (HOPE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

28 days ago · globenewswire.com

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).

2 months ago · globenewswire.com

– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Company's lead asset for the treatment of Duchenne muscular dystrophy (DMD), will be presented in a late-breaking poster and an oral presentation at the 31 st Annual Congress of the World Muscle Society (WMS 2026), taking place September 29 – October 3, 2026, in Hiroshima, Japan.

3 months ago · globenewswire.com

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Cardiac Benefit--

3 months ago · businesswire.com

NEW YORK--(BUSINESS WIRE)--Bank of Hope, subsidiary of Hope Bancorp, Inc. (NASDAQ: HOPE), is expanding the ways it connects with customers and community members through a creative branding campaign centered on a sponsorship of 'BTS THE CITY ARIRANG NEW YORK'. Celebrating ‘BTS THE CITY ARIRANG NEW YORK' as people from around the world gather in New York City, this campaign serves as a unique activation targeted at today's consumers who seek meaningful relationships with the brands with which the.

3 months ago · seekingalpha.com

Hope Bancorp, Inc. (HOPE) Q2 2026 Earnings Call Transcript

3 months ago · zacks.com

While the top- and bottom-line numbers for Hope Bancorp (HOPE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.